Jennifer B Marks Selected Research

Type 2 Diabetes Mellitus (MODY)

10/2014	Blood pressure and pulse pressure effects on renal outcomes in the Veterans Affairs Diabetes Trial (VADT).
9/2008	How do detemir and glargine compare when added to oral agents in insulin-naïve patients with type 2 diabetes mellitus?
9/2003	Continuous subcutaneous insulin infusion and multiple daily injection therapy are equally effective in type 2 diabetes: a randomized, parallel-group, 24-week study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jennifer B Marks Research Topics

Disease

14	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 01/2022 - 01/2003
3	Autoimmune Diseases (Autoimmune Disease) 01/2019 - 07/2011
3	Insulin Resistance 07/2015 - 01/2009
3	Type 2 Diabetes Mellitus (MODY) 10/2014 - 09/2003
2	Inflammation (Inflammations) 02/2012 - 01/2009
2	Infections 07/2011 - 11/2009
2	Neutropenia 07/2011 - 11/2009
2	Hypoglycemia (Reactive Hypoglycemia) 09/2008 - 01/2003
1	Disease Progression 01/2019
1	Dyslipidemias (Dyslipidemia) 07/2015
1	Injection Site Reaction 06/2013
1	Essential Hypertension 02/2012
1	Obesity 02/2012
1	Hypertension (High Blood Pressure) 02/2012
1	Abdominal Obesity 02/2012
1	Hyperlipidemias (Hyperlipidemia) 01/2009
1	Weight Gain 09/2008
1	Hyperglycemia 01/2003
1	Ketosis 01/2003

Drug/Important Bio-Agent (IBA)

9	Glucose (Dextrose)FDA LinkGeneric 01/2022 - 01/2003
6	Insulin (Novolin)FDA Link 01/2022 - 09/2003
4	C-PeptideIBA 11/2020 - 06/2013
2	AutoantibodiesIBA 11/2020 - 01/2018
2	Antilymphocyte Serum (Anti-Thymocyte Globulin)IBA 01/2019 - 09/2018
2	Monoclonal AntibodiesIBA 01/2019 - 02/2014
2	Abatacept (Orencia)FDA Link 04/2014 - 07/2011
2	Rituximab (Mabthera)FDA Link 02/2014 - 11/2009
1	Indicators and Reagents (Reagents)IBA 01/2022
1	Fc Receptors (Fc Receptor)IBA 01/2019
1	teplizumabIBA 01/2019
1	pegylated granulocyte colony-stimulating factorIBA 09/2018
1	CarbohydratesIBA 07/2015
1	Interleukin-1 Receptors (Interleukin 1 Receptor)IBA 06/2013
1	canakinumab FDA Link 06/2013
1	Immunomodulating AgentsIBA 06/2013
1	Interleukin-1 (Interleukin 1)IBA 06/2013
1	Interleukin 1 Receptor Antagonist Protein (Anakinra)FDA Link 06/2013
1	Angiotensin IIIBA 02/2012
1	Angiotensin Receptors (Angiotensin II Receptor)IBA 02/2012
1	Losartan (Cozaar)FDA LinkGeneric 02/2012
1	Angiotensin Receptor AntagonistsIBA 02/2012
1	Aluminum Hydroxide (Algeldrate)FDA Link 07/2011
1	Glutamate Decarboxylase (Decarboxylase, Glutamate)IBA 07/2011
1	AntigensIBA 07/2011
1	aluminum sulfate (alum)IBA 07/2011
1	VaccinesIBA 07/2011
1	Oxygen (Dioxygen)IBA 01/2009
1	Hypoglycemic Agents (Hypoglycemics)IBA 09/2008
1	Insulin Glargine (Lantus)FDA Link 09/2008
1	Insulin Aspart (NovoLog)FDA Link 09/2003
1	ElectrolytesIBA 01/2003
1	AcidsIBA 01/2003

Therapy/Procedure

5	Therapeutics 01/2019 - 09/2003
2	Injections 07/2011 - 09/2003
1	Carbohydrate Loading Diet 07/2015
1	Withholding Treatment 04/2014
1	Immunotherapy 07/2011
1	Perioperative Period 01/2003